The Medicaid Drug Utilization Review (DUR) program conducted by Medicaid state agencies promotes patient safety through state-administered drug utilization management tools and systems in a 2-phase process.
Part of this information was presented as a poster at the 2016 Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.
The Importance and Benefits of Smoking-Cessation Therapy
The Medicaid Drug Utilization Review (DUR) program promotes patient safety through state-administered drug utilization management tools and systems.
Is the Federal Drug Utilization Review Requirement Just Red Tape or an Enlightened State of Flexibility?
Washington, DC—A panel discussion on health and drug politics took place at the Sixth Annual Conference of the Association for Value-Based Cancer Care. The expert panel included Kavita Patel, MD, Johns Hopkins Medicine, Baltimore; Dan Todd, Principal of Todd Strategy, Washington, DC; and Liz Fowler, Vice President, Global Health Policy, Johnson & Johnson. The panel discussed what is working in healthcare, what is not, and where cancer care fits into it all.

The Affordable Care Act (ACA) initiated health insurance exchanges, or marketplaces, with health plans offering subsidies for plan members, to help individuals, families, and small businesses find health plans that fit their specific needs. By the end of the first open enrollment period, more than 8 million Americans selected qualified health plans through the ACA-initiated health insurance marketplace, and by February 2015, more than 10 million people enrolled and paid for health coverage through those plans in these marketplaces. Under state and federal rules and regulations, the ACA allowed insurers to offer a variety of well-defined health insurance plans and compete through the marketplace.

Health Plan Subsidies, Prescription Drugs, and Cost
The cost of cancer care in the United States continues to rise, in part as a result of the aging population and improvements in diagnosis, treatment, and survival. These costs are projected to reach $173 billion in 2020, representing a 39% increase from 2010
Implementing Payment Reform in Oncology: Benefits and Challenges
This article explores how oncology researchers can create tools to adapt patient-reported outcomes (PROs) in their data collection.
Patient-Reported Outcomes in Oncology: Challenges and Opportunities for All Stakeholders
In a 2013 report, the IMS Institute for Healthcare Informatics estimated that the United States spent more than $213 billion on unnecessary medical expenses as a result of irresponsible medication use.
Is It Time to Revisit Medicare Part D?
Let us travel back in time to 2002. “Managed care” had been identified as the source of everything wrong with the healthcare system...
Financing Drug Innovation: Cost versus Cure
Previous studies have shown that there were greater racial and ethnic disparities among individuals who were ineligible for medication therapy management (MTM) services than among MTM-eligible individuals before the implementation of Medicare Part D in 2006.
Medication Therapy Management, Medicare, and Disparities in Population Health
Page 1 of 4
Results 1 - 10 of 39
  •  Association for Value-Based Cancer Care
  • Oncology Practice Management
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Rheumatology Practice Management
  • Urology Practice Management
  • Lynx CME